Lessons learned from the ATLAS performance studies of the Iberian Cloud for the first LHC running period

In this contribution we describe the performance of the Iberian (Spain and Portugal) ATLAS cloud during the first LHC running period (March 2010-January 2013) in the context of the GRID Computing and Data Distribution Model. The evolution of the resources for CPU, disk and tape in the Iberian Tier-1 and Tier-2s is summarized. The data distribution over all ATLAS destinations is shown, focusing on the number of files transferred and the size of the data. The status and distribution of simulation and analysis jobs within the cloud are discussed. The Distributed Analysis tools used to perform physics analysis are explained as well. Cloud performance in terms of the availability and reliability of its sites is discussed. The effect of the changes in the ATLAS Computing Model on the cloud is analyzed. Finally, the readiness of the Iberian Cloud towards the first Long Shutdown (LS1) is evaluated and an outline of the foreseen actions to take in the coming years is given. The shutdown will be a good opportunity to improve and evolve the ATLAS Distributed Computing system to prepare for the future challenges of the LHC operation.Peer Reviewe

International Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated module

We report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention's (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health care–associated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC's ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC's ICUs was similar to that reported from ICUs in the U.S. in the CDC's NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central line–associated bloodstream infection in the INICC's ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC's ICUs compared with the ICUs of the CDC's NHSN